Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.06 USD

41.06
1,675,971

+0.74 (1.84%)

Updated Aug 13, 2024 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Stock Reports for IBM, Texas Instruments & Glaxo

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Texas Instruments (TXN) and Glaxo (GSK).

    Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

    by Zacks Equity Research

    Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

      Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

      by Zacks Equity Research

      Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

        Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

        by Zacks Equity Research

        Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

          Mylan (MYL) Launches Generic Version of Lilly's Adcirca

          by Zacks Equity Research

          Mylan (MYL) launches the first generic version of Lilly's Adcirca for the treatment of pulmonary arterial hypertension to improve exercise ability.

            Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

            by Zacks Equity Research

            Mylan is expected to loose ground after its second-quarter results miss estimates. The cut in guidance is disappointing as well.

              Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates

              by Zacks Equity Research

              Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.

                Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?

                by Zacks Equity Research

                Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).

                  Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval

                  by Zacks Equity Research

                  Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.

                    Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up

                    by Zacks Equity Research

                    Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.

                      Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

                      by Zacks Equity Research

                      Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

                        Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

                        by Zacks Equity Research

                        Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

                          Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength

                          by Zacks Equity Research

                          Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

                            Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up

                            by Zacks Equity Research

                            Glaxo (GSK) beats both earnings and revenues in the second quarter of 2018, and signs a four-year collaboration with 23andMe and invests $300 million for the same.

                              Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit

                              by Zacks Equity Research

                              Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.

                                ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions

                                by Zacks Equity Research

                                The pharma/biotech industry has witnessed a solid start in the Q2 reporting cycle. Let's see if leading players - Merck (MRK) and AbbVie (ABBV) - can contribute further to the encouraging numbers.

                                  Merck's Keytruda Improves Survival in Head/Neck Cancer Study

                                  by Zacks Equity Research

                                  Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.

                                    Glaxo (GSK) Beats on both Earnings and Revenue in Q2

                                    by Zacks Equity Research

                                    Glaxo beat both earnings and sales estimates in the second quarter of 2018.

                                      Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?

                                      by Zacks Equity Research

                                      Merck's (MRK) new products like Keytruda and Bridion are likely to drive second-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

                                        Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK

                                        by Zacks Equity Research

                                        The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.

                                          Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?

                                          by Zacks Equity Research

                                          Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

                                            What's in the Cards for Glaxo (GSK) This Earnings Season?

                                            by Zacks Equity Research

                                            Glaxo's (GSK) Pharmaceuticals and Vaccines segments are likely to boost sales in Q2 earnings.

                                              Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion

                                              by Zacks Equity Research

                                              Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.

                                                J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

                                                by Zacks Equity Research

                                                The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

                                                  Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto

                                                  by Zacks Equity Research

                                                  Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.